Navigation Links
WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting
Date:5/9/2008

OAKLAND, Calif., May 9 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX: WHT) Since January 2008, World Heart Corporation (the "Company") has aggressively pursued various financing alternatives to raise additional capital, including through equity financing transactions and corporate collaborations, in order to continue operations. At April 30, 2008, the Company had cash and cash equivalents of approximately $0.5 million and current liabilities of approximately $2.6 million. On May 2, 2008, the Company learned that its potential primary investor may not be able to give its assurance of commitment to allow the Company to access capital to meet current financing needs. This information resulted in the Company making the determination that its available cash would be insufficient to pay the Company's obligations as they become due, which constitutes an event of default under the Company's secured convertible promissory note in the amount of $5.0 million issued on December 11, 2007 to Abiomed, Inc. This event of default under the note results in the outstanding principal balance of the note, together with accrued but unpaid interest and any other amounts owing under the Abiomed note documents, becoming immediately due and payable to Abiomed. The note is secured by security agreements entered into by the Company and the Company's wholly-owned subsidiary, World Heart, Inc. ("WHI"), in favor of Abiomed, that grant a security interest in all of their respective assets. Abiomed could exercise its remedies under law and under the security agreements, including foreclosing on the assets of the Company and WHI. An event of default also permits Abiomed to terminate the clinical and marketing support services agreement.

The Company has an immediate need for additional capital in order to satisfy its obligations and to continue operations. The Company continues to aggressively pursue various financing alternatives but its efforts to raise additional capital have not been successful as of the date of this report. The Company estimates that it has cash available to continue operations only through the latter part of May 2008. If the Company is unable to secure additional funding, it will be forced to take extraordinary business measures which could include filing for bankruptcy, ceasing operations and liquidating assets.

On May 5, 2008, the Company was informed by Robert J. Majteles that he is resigning from the Board of Directors and all of the committees of the Board, effective immediately. The Company intends to reconstitute all of the committees of the Board, such that Mr. William C. Garriock, Dr. Michael Estes and Mr. Gary Goertz, the three remaining independent directors, will be members of each of the committees.

On April 29, 2008, the Company held its Annual Meeting of Shareholders where proposals for shareholders' vote were presented for the following purposes:

(1) to receive and to consider the Company's audited consolidated

financial statements for the year ended December 31, 2007, that have

been prepared in accordance with generally accepted accounting

principles in the United States, together with the report of the

auditors thereon;

(2) to elect directors to serve until the next annual meeting of the

shareholders or until their successors are elected or appointed,

unless the office is vacated earlier;

(3) to appoint Burr, Pilger & Mayer LLP as independent auditors of the

Company and to authorize the directors to fix their remuneration; and

(4) to approve conversion of the secured promissory note in the principal

amount of up to US$5,000,000, previously issued to Abiomed

convertible at Abiomed's option into the Company's common shares at

US$1.748948 per share, subject to adjustments, including any

conversion of interest owed, and approval of the exercise of a five

year warrant to purchase up to 3,400,000 common shares of the

Company, exercisable at US$0.01 per share, issued to Abiomed in

connection with the secured promissory note.

The election of directors, the appointment of the auditors and the conversion of the note and exercise of the warrant issued to Abiomed were carried by a majority of the votes at the meeting in person or by proxy. A copy of the Voting Results, which includes the percentage outcome of the votes cast, is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include any statements regarding the Company's ability to regain compliance with the NASDAQ Capital Market listing requirements, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: the Company's immediate need for additional capital, risks in product development and market acceptance of and demand for the Company's products; delisting from the NASDAQ Stock Market if compliance with the listing standards, including the Minimum Bid Price Rule and other minimum standards, is not regained; and other risks detailed in the Corporation's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-KSB for the year ended December 31, 2007.


'/>"/>
SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WorldHeart 10-KSB Audit Report Includes Going Concern Qualification
2. WorldHeart Schedules Teleconference
3. Cardium Reports on First Quarter 2008 Highlights and Financial Results
4. Novavax Reports First Quarter 2008 Financial Results
5. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
6. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers ... research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of the latest paper by its Science Editor, Dr. Elisabeth Bik, in the ... Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
(Date:1/18/2017)... 2017  Caris Life Sciences, a leading innovator ... largest private funder of pancreatic cancer research, are ... impact of immunotherapy in the treatment of pancreatic ... to identify potential trial candidates based on biomarker ... and study investigators. The Lustgarten Foundation is a ...
Breaking Biology Technology:
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
Breaking Biology News(10 mins):